{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:19:10Z","timestamp":1777339150618,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1186\/1472-6874-8-24","type":"journal-article","created":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T19:14:16Z","timestamp":1230059656000},"source":"Crossref","is-referenced-by-count":16,"title":["Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates"],"prefix":"10.1186","volume":"8","author":[{"given":"Shonda A","family":"Foster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S","family":"Meadows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhardt M","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey R","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,23]]},"reference":[{"key":"141_CR1","volume-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","author":"U.S. Department of Health and Human Services","year":"2004","unstructured":"U.S. Department of Health and Human Services: Bone Health and Osteoporosis: A Report of the Surgeon General. 2004, Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General"},{"key":"141_CR2","unstructured":"Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000, 17: 1-45."},{"key":"141_CR3","doi-asserted-by":"publisher","first-page":"505S","DOI":"10.1016\/8756-3282(95)00258-4","volume":"17","author":"BL Riggs","year":"1995","unstructured":"Riggs BL, Melton LJ: The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995, 17: 505S-511S. 10.1016\/8756-3282(95)00258-4.","journal-title":"Bone"},{"key":"141_CR4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation Investigators: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999, 282: 637-645. 10.1001\/jama.282.7.637.","journal-title":"JAMA"},{"key":"141_CR5","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","volume":"87","author":"PD Delmas","year":"2002","unstructured":"Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster J, Pols HA, Recker RR, Harris ST, Wu Wentao, Genant HK, Black DM, Eastell R: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002, 87: 3609-3617. 10.1210\/jc.87.8.3609.","journal-title":"J Clin Endocrinol Metab"},{"key":"141_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2796.2004.01317.x","volume":"255","author":"PN Sambrook","year":"2004","unstructured":"Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME: Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX\u00ae versus EVISTA\u00ae Comparison Trial) International. J Intern Med. 2004, 255: 503-511. 10.1111\/j.1365-2796.2004.01317.x.","journal-title":"J Intern Med"},{"key":"141_CR7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999, 282: 1344-1352. 10.1001\/jama.282.14.1344.","journal-title":"JAMA"},{"key":"141_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0889-857X(05)70192-7","volume":"27","author":"EG Lufkin","year":"2001","unstructured":"Lufkin EG, Wong M, Deal C: The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum Dis Clin North Am. 2001, 27: 163-185. 10.1016\/S0889-857X(05)70192-7.","journal-title":"Rheum Dis Clin North Am"},{"key":"141_CR9","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, for the CORE investigators: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004, 96: 1751-1761.","journal-title":"J Natl Cancer Inst"},{"key":"141_CR10","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1185\/030079905X61839","volume":"21","author":"S Martino","year":"2005","unstructured":"Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL: Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005, 21: 1441-1452. 10.1185\/030079905X61839.","journal-title":"Curr Med Res Opin"},{"key":"141_CR11","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan C, Wolmark N, for the National Surgical Adjuvant Breast and Bowel Project (NSABP): Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006, 295: 2727-2741. 10.1001\/jama.295.23.joc60074.","journal-title":"JAMA"},{"key":"141_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006, 355: 125-137. 10.1056\/NEJMoa062462.","journal-title":"N Engl J Med"},{"key":"141_CR13","unstructured":"Raloxifene (Evista) product label. 2007, Eli Lilly and Company, Indianapolis"},{"key":"141_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/00912700122010050","volume":"41","author":"M Kleerekoper","year":"2001","unstructured":"Kleerekoper M, Schein JR: Comparative safety of bone remodeling agents with a focus on osteoporosis therapy. J Clin Pharmacol. 2001, 41: 239-250. 10.1177\/00912700122010050.","journal-title":"J Clin Pharmacol"},{"key":"141_CR15","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Onco. 2005, 23: 8580-8587. 10.1200\/JCO.2005.02.8670.","journal-title":"J Clin Onco"},{"key":"141_CR16","unstructured":"Ibandronate (Boniva) product label. 2005, Roche GlaxoSmithKlein, Nutley, NJ"},{"key":"141_CR17","unstructured":"Alendronate (Fosamax) product label. 2005, Merck & Co, Inc., Whitehouse Station, NJ"},{"key":"141_CR18","unstructured":"Risedronate (Actonel) product label. 2005, Proctor & Gamble Pharmaceuticals, Cincinnati, OH 45202"},{"key":"141_CR19","unstructured":"HEDIS Guidelines. Accessed August 9, 2005., [\n                    http:\/\/www.ncqa.org\n                    \n                  ]"},{"key":"141_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992, 45: 613-19. 10.1016\/0895-4356(92)90133-8.","journal-title":"J Clin Epidemiol"},{"key":"141_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/0003-4819-148-9-200805060-00003","volume":"148","author":"SM Cadarette","year":"2008","unstructured":"Cadarette SM, Katz JN, Brookhart A, Sturmer T, Stedman MR, Solomon DH: Relative effectiveness of osteoporosis drugs for preventing nonvertebral fractures. Ann Intern Med. 2008, 148: 637-46.","journal-title":"Ann Intern Med"},{"key":"141_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-199916010-00001","volume":"16","author":"HG Birnbaum","year":"1999","unstructured":"Birnbaum HG, Cremieux PY, Greenberg PG, LeLorier J, Ostrander J, Venditti L: Using healthcare claims data for outcomes research and pharmacoeconomic analysis. Pharmacoeconomics. 1999, 16: 1-8. 10.2165\/00019053-199916010-00001.","journal-title":"Pharmacoeconomics"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6874-8-24\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-8-24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-8-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-8-24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T04:37:17Z","timestamp":1548218237000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/1472-6874-8-24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1186\/1472-6874-8-24","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]},"article-number":"24"}}